Tamsulosin versus terazosin for benign prostatic hyperplasia: A systematic review

Systems Biology in Reproductive Medicine

Volumn 55, Issue 4, 2009, Pages 129-136

  Dong, Zhilong ^a   Wang, Zhiping ^a   Yang, Kehu ^a   Liu, Yali ^a   Gao, Wenhui ^b   Chen, Wenyuan ^c  

^a LANZHOU UNIVERSITY   (China)

^b Danma Town Healthy Care Station   (China)

^c Wuwei Tumor Hospital   (China)

Author keywords

Benign prostatic hyperplasia; Tamsulosin; Terazosin

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; TAMSULOSIN; TERAZOSIN;

ASTHENIA; BIBLIOGRAPHIC DATABASE; BLOOD PRESSURE; BLOOD VESSEL TONE; CLINICAL TRIAL; COCHRANE LIBRARY; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; EJACULATION; EMBASE; ERECTILE DYSFUNCTION; HUMAN; HYPOTENSION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LONG TERM CARE; LOWER URINARY TRACT SYMPTOM; MEDLINE; META ANALYSIS; ORGAN WEIGHT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESIDUAL VOLUME; REVIEW; RISK FACTOR; SENSITIVITY ANALYSIS; STANDING; SYSTEMATIC REVIEW; TUMOR VOLUME; URINE FLOW RATE; VAS DEFERENS; XEROSTOMIA;

ADRENERGIC ALPHA-ANTAGONISTS; HUMANS; MALE; PRAZOSIN; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES;

EID: 72949093736     PISSN: 19396368     EISSN: 19396368     Source Type: Journal    
DOI: 10.3109/19396360902833235     Document Type: Review

References (37)

1. Barry, M. J., Adolfsson, J. and Batista, J. E. (1998) Committee 6: Measuring the symptoms and health impact of benign prostatic hyperplasia and its treatments. Health Publication:265-321.
2. Barry, M. J., Fowler, F. J., Bin, L., Pitts, J. C., Harris, C. J. and Mulley, A. G. (1997) The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol 157:10-15.
3. Bosch, J. L., Hop, W. C., Kirkels, W. J. and Schroder, F. H. (1995) Natural history of benign prostatic hyperplasia: Appropriate case definition and estimation of its prevalence in the community. Urology 46(Suppl A):34-40.
4. Brawer, M. K., Adams, G. and Epstein, H. (1993) Terazosin in the treatment of benign prostatic hyperplasia. Arch Fam Med 2:929-935.
5. Chapple, C. R., Carter, P. and Christmas, T. J. (1994) A three month double-blind placebo controlled study of doxazosin as treatment for benign prostatic bladder outflow obstruction. Br J Urol 74:50-56.
6. Ford, A. P., Williams, T. J., Blue, D. R. and Clarke, D. E. (1994) α1-adrenoreceptor classification: Sharpening Occam's razor. Trends Pharmacol Sci 15:167-170.
7. Grasso, M., Fortuna, F., Lania, C. and Blanco, S. (2006) Ejaculatory disorders and α1-adrenoceptor antagonists therapy: Clinical and experimental researches. J Transl Med 4:31.
8. Hieble, J. P., Bylund, D. B. and Clarke, D. E. (1995) Recommendation for nomenclature of α1-adrenoreceptor: Consensus update. Pharmacol Rev 47:267-270.
9. Hieble, J. P., Caine, M. and Zalaznik, E. (1985) In vitro characterization of the a-adrenoreceptors in human prostate. Eur J Pharmacol 107:111-117.
10. Hou, S. C., Dong, S. G. and Wang, X. S. (1999) Clinical study of Tamsulosin treatment of benign prostatic hyperplasia. J Modern Urol 4:254-259.
11. Jacobsen, S. J., Girman, C. J., Guess, H. A., Rhodes, T., Oesterling, J. E. and Lieber, M. M. (1996) Natural history of prostatism: Longitudinal changes in voiding symptoms in community dwelling men. J Urol 155:595-600.
12. Jacobsen, S., Jacobson, D. and Girman, C. (1997) Natural history of prostatism: Risk factors for acute urinary retention. J Urol 158:4817.
13. Jardin, A., Bensadoun, H. and Delauche-Cavallier, M. C. (1994) Long term treatment of benign prostatic hyperplasia with alfuzosin: A 24-30 month survey. Br J Urol 74:579-584.
14. Jing, L. (1999) Comparison effectiveness two selective a-blocker receptor blocker treatment of benign prostatic hyperplasia. Journal of Jiangsu Pharmacy 7(1):312-316.
15. Kirby, R. S., Coppinger, S. W. C., Corcoran, M. O., Chapple, C. R., Flannagan, M. and Milroy, E. J. G. (1987) Prazosin in the treatment of prostatic obstruction: A placebo-control study. Br J Urol 60:136-142.
16. Kunisawa, Y., Kawabe, K., Niijima, T., Honda, K. and Takenaka, T. (1985) A pharmacological study of a-adrenergic receptor subtypes in smooth muscle of human urinary bladder and prostatic urethra. J Urol 134:396-398.
17. Kyprianou, N., Tu, H. and Jacobs, S. C. (1996) Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum. Pathol 27:668-675.
18. Lee, E. and Lee, C. (1997) Clinical comparisons of selective and nonselective a1A-adrenoreceptor antagonists in benign prostatic hyperplasia: Studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 80(4):606-611.
19. Lepor, H. (1990) Role of α1-adrenergic blockers in the treatment of benign prostatic hyperplasia. Prostate 3(Suppl):75-84. (Pubitemid 20127953)
20. Lepor, H., Auerbach, S. and Puras-Baez, A. (1992) A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 148:1467-1474.
21. Lu, G. C. (1998) Preliminary experience of Tamsulosin treatment of benign prostatic hyperplasia. Journal of Clinical Urology 13(1):46-47.
22. McConnell, J., Bruskewitz, R. and Walsh, P. (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338:557-563.
23. McVary, K. T. (2005) Sexual function and a-blockers. Rev Urol 7(Suppl. 8):S3-S11.
24. Narayan, P. and Lepor, H. (2001) Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology 57:466-470.
25. Narayan, P., O'Leary, M. P. and Davidai, G. (2005) Early efficacy of tamsulosin versus terazosin in the treatment of men with benign prostatic hyperplasia: A randomized, open-label trial. The Journal of Applied Research 5:237-245.
26. Na, Y. J., Guo, Y. L. and Gu, F. L. (1998) Clinical comparisons of selective and non-selective a1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: Studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. J Med 29(5-6):289-304.
27. Na, Y. Q., Wang, D. and Jing, J. (1996) Selective a-blocker receptor blocker treatment of benign prostatic hyperplasia. Journal of Chinese Urology 6(1 7):327-329.
28. Nordling, J. and Hald, T. (1997) BPH versus LUTS: Reflections on lower urinary tract symptoms in search of a definition of clinical benign prostatic hyperplasia. European Urology Update Series 6:54-60.
29. Oishi, K., Boyle, P. and Barry, M. J. (1998) Committee 1: Epidemiology and natural history of benign prostatic hyperplasia. Health Publication: 23-59.
30. Okada, H., Kamidono, S., Yoshioka, T., Okuyama, A., Ozono, S., Hirao, Y., Okajima, E., Yamamoto, K., Kishimoto, T., Park, Y. and Kurita, T. (2000) A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. BJU Int 85(6):676-681.
31. Ravish, I. R., Nerli, R. B. and Amarkhed, S. S. (2007) Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate. Arch Androl 53:17-20.
32. Roehrborn, C. G., Oesterling, J. E. and Arbor, A. (1995) Hytrin community assessment trial (HYCAT): Evaluation of the clinical effectiveness of terazosin versus placebo in the treatment of patients with symptomatic benign prostatic hyperplasia. J Urol 153(Suppl):272 abstr 175.
33. Suzuki, Y., Katoh, T., Isurugi, K., Obara, W., Omori, S., Goto, Y., Fujioka, T. and Numasato, S. (2001) The efficacy and safety of terazosin and tamsulosin in patients with urinary disturbance accompanying prostatic hypertrophy. Hinyokika Kiyo 47(1):15-21.
34. Tsujii, T. (2000) Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: A short-term open, randomized multicenter study. International Journal of Urology 7:199-205.
35. Xu, X. R., Zhong, W. D. and Wang, L. S. (2000) Effectiveness analysis tamsulosin of and terazosin treatment of benign prostatic hyperplasia. Journal of Practical Medicine 16(10):816-817.
36. Yamada, S., Tanaka, C., Kimura, R. and Kawabe, K. (1994) α1-adrenoreceptors in human prostate: Characterization and binding characteristics of alpha-1-antagonists. Life Sci 54:1845-1854.
37. Zhong, W. D., Cai, Y. B. and Hu, J. B. (2000) Efficacy-cost analysis of α1-blocker receptor blocker treatment of benign prostatic hyperplasia. Academic Journal of Guangdong College of Pharmacy 6:123-128.